Agios Reports Business Highlights and Third Quarter 2022 Financial Results
November 03, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
– U.S. PYRUKYND® (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 – – Received Positive CHMP...
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
October 27, 2022 16:01 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and TORONTO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically...
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
October 20, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined...
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
September 26, 2022 19:13 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined...
Agios Appoints Cecilia Jones as Chief Financial Officer
September 19, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined...
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
September 16, 2022 06:41 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined...
Agios to Participate in September Investor Conferences
August 24, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined...
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
August 18, 2022 18:35 ET
|
Agios Pharmaceuticals, Inc.
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Regularly Transfused, PYRUKYND® Demonstrated a Statistically Significant and Clinically Meaningful Reduction in Transfusion Burden – –...
Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors
August 15, 2022 08:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia
August 11, 2022 18:35 ET
|
Agios Pharmaceuticals, Inc.
– In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND® Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 – – PYRUKYND® Safety...